MARKET

AMTI

AMTI

Applied Molecular Transport Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.900
-0.010
-0.34%
After Hours: 2.920 +0.02 +0.69% 19:52 07/01 EDT
OPEN
2.900
PREV CLOSE
2.910
HIGH
3.070
LOW
2.860
VOLUME
122.46K
TURNOVER
0
52 WEEK HIGH
47.00
52 WEEK LOW
2.670
MARKET CAP
112.10M
P/E (TTM)
-0.9116
1D
5D
1M
3M
1Y
5Y
Applied Molecular Transport to Present at Upcoming June Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in fireside chats at the following investor conferences: Eve...
GlobeNewswire · 06/02 12:00
44 Stocks Moving In Wednesday's Mid-Day Session
Gainers
Benzinga · 06/01 16:14
10 Biggest Price Target Changes For Friday
Telsey Advisory Group lowered the price target for Best Buy Co., Inc. (NYSE: BBY) from $130 to $90. Best Buy shares rose 0.4% to $73.58 in pre-market trading.
Benzinga · 05/20 12:04
--SVB Securities Adjusts Price Target on Applied Molecular Transport to $21 From $60, Keeps Outperform Rating
MT Newswires · 05/20 05:58
JMP Securities Adjusts Price Target on Applied Molecular Transport to $50 From $86, Maintains Market Outperform Rating
MT Newswires · 05/19 07:44
Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs
Benzinga · 05/18 16:41
Applied Molecular to prioritize resources on lead clinical programs, reduce workforce
Applied Molecular Transport (NASDAQ:AMTI) stock has lost 5.2% to $4.05 in Wednesday morning trade, after the clinical-stage biopharmaceutical company said it would prioritize its resources on its lead clinical programs, reduce its
Seekingalpha · 05/18 14:09
BRIEF-Applied Molecular Transport Inc. - Implements Cost Reductions To Support Strategic Prioritization And Extend Estimated Cash Runway Into 2024
reuters.com · 05/18 12:43
More
No Data
Learn about the latest financial forecast of AMTI. Analyze the recent business situations of Applied Molecular Transport Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

75.00%Strong Buy
25.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AMTI stock price target is 23.68 with a high estimate of 50.00 and a low estimate of 10.00.
High50.00
Average23.68
Low10.00
Current 2.900
EPS
Actual
Estimate
-0.88-0.66-0.44-0.22
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 87
Institutional Holdings: 28.32M
% Owned: 73.26%
Shares Outstanding: 38.65M
TypeInstitutionsShares
Increased
24
1.54M
New
12
1.31M
Decreased
26
967.67K
Sold Out
19
1.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Executive Director
Graham Cooper
President/Chief Operating Officer
Shawn Cross
Chief Executive Officer/Co-Founder/Director
Tahir Mahmood
Chief Financial Officer
Brandon Hants
Senior Vice President
Carolyn Finkle
Senior Vice President
Derek Maclean
Chief Technology Officer
Douglas Rich
Vice President
Andy Whitney
Other
Elizabeth Bhatt
Other
Bittoo Kanwar
Lead Director/Independent Director
Holly Schachner
Director
Randall Mrsny
Independent Director
Charlene Banard
Independent Director
David Lamond
Independent Director
John Smither
Independent Director
Aaron VanDevender
No Data
No Data
About AMTI
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform, including AMT-101, an oral gastrointestinal (GI)-selective oral fusion of interleukin 10 (IL-10) that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of interleukin 22 (IL-22). Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.

Webull offers kinds of Applied Molecular Transport Inc. stock information, including NASDAQ:AMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMTI stock methods without spending real money on the virtual paper trading platform.